News | May 11, 2023
FSD Pharma completes dosing of first cohort in Phase I clinical trial of Lucid-MS
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
Twelve hospitals across India will be part of the network which will support the trial in India
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Phase III trial also demonstrated a statistically significant reduction (14%) in hospitalization for any cause, bringing potential relief for patients and reducing burden on healthcare systems
Subscribe To Our Newsletter & Stay Updated
